Gitnux/Report 2026

Space Biotech Industry Statistics

ISS-linked funding reached $251M in FY2025, explore the figures behind market size, company activity, and automation-led throughput trends.
15Statistics
24Sources
2Sections
14mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The space biotech industry at a glance

Space biotech remains an emerging, research-led industry: ISS National Lab-linked startups raised $251 million in fiscal 2025, while commercial platforms expand drug discovery, disease modeling and in-space biomanufacturing.

$251M[9]
ISS-linked funding in FY2025
750+[3]
ISS experiments in 2025
$2.5B[9]
Cumulative post-flight funding
331[9]
ISS ecosystem investors in FY2025
Market share & regions
No reliable source identified that measures space biotech market share by region. Available evidence shows activity centered on U.S.-led ISS and commercial-LEO programs, with European participation including Luxembourg-based Exobiosphere, which reported 13 employees and €2 million in internal R&D investment in its 2025 directory profile.[10][9]
Segmentation
Space biotech activity is segmented into microgravity drug discovery and disease modeling, cell and tissue research, protein and crystal production, and in-space manufacturing of biological materials. NASA’s FY2026–27 STTR solicitation specifically targets biotechnology materials and products for Earth applications, including solutions for childhood diseases.[3]
Key players & concentration
The ecosystem is fragmented among research agencies, launch and station operators, pharmaceutical partners, and specialist startups rather than dominated by a published market-share leader. ISS National Lab listed 331 financial and corporate investor participants in FY2025, while companies named in its startup ecosystem included Axonis Therapeutics, Aphios, Eascra Biotech, Sachi Bioworks and Tympanogen.[9]
Pricing
No reliable industry-wide pricing benchmark was identified. Commercial access is typically sold as mission, payload, laboratory or platform services; Exobiosphere is developing an automated Orbital High-Throughput Screening platform designed to run thousands of experiments, but its public materials do not disclose customer pricing.[11][10]
Trends, drivers & challenges
The main growth drivers are commercial low-Earth-orbit destinations, automation, demand for improved disease models and biomanufacturing, and NASA support for Earth-focused in-space production. Key constraints remain launch and crew access, limited repeatability and scale, long validation cycles, regulatory requirements, and uncertain return on investment for pharmaceutical customers.[3][12]
Consumer behavior & competition
The primary buyers are pharmaceutical and biotechnology companies, research institutes, health agencies and space companies, rather than mass-market consumers. Competition is focused on proving that microgravity produces commercially valuable results: Axiom and Aspera Biomedicines advanced a microgravity-tested cancer drug toward clinical trials, while Exobiosphere is building high-throughput orbital screening capability.[10][11]
M&A
No reliable, material space-biotech merger or acquisition with a disclosed transaction value was identified through November 20, 2026. Public activity remains more concentrated in partnerships and strategic collaborations, including the October 2026 Axiom Space–Exobiosphere memorandum of understanding.[11]
Regulation
Space-biotech products intended for Earth markets must meet applicable medical and pharmaceutical standards; NASA’s FY2026–27 STTR program explicitly requires biotechnology products developed for Earth applications to meet FDA standards. Clinical development remains subject to FDA requirements, as illustrated by Aspera Biomedicines’ drug entering trials under an active Investigational New Drug status.[3][11]
Latest news
In October 2026, Axiom Space and Exobiosphere signed an MoU to advance drug discovery using Exobiosphere’s automated Orbital High-Throughput Screening platform on private astronaut missions and Axiom Station. The companies said the platform is intended to run thousands of experiments with matched ground controls and explore in-space manufacturing in low Earth orbit.[11]

02 Ranking

Top 9 Companies in the Space Biotech Industry

The leading companies in the space biotech industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Varda Space Industries stands out for orbital pharmaceutical materials processing because it returns pharmaceutical materials to Earth using its W-Series vehicles, while Sierra Space focuses on orbital biotech and pharmaceutical manufacturing since it develops platforms on commercial space stations.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in orbital pharmaceutical processing

    Varda Space Industries

    US

    Ranked #1 · 9.7 · Orbital pharmaceutical processing

    Why we picked it: It processes pharmaceutical materials in orbit and returns them to Earth using W-Series vehicles.

  2. Leader in orbital biotech manufacturing platforms

    Sierra Space

    US

    Ranked #2 · 9.0 · Orbital biotech manufacturing platforms

    Why we picked it: It develops orbital biotech and pharmaceutical manufacturing platforms on commercial space stations.

  3. Leader in ISS life science payload hardware

    BioServe Space Technologies

    US

    Ranked #3 · 8.8 · ISS life science payload hardware

    Why we picked it: It provides hardware for life science experiments conducted on the ISS.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 9 companies in the space biotech industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Varda Space Industries

Orbital pharmaceutical processing · US

9.7
2

Sierra Space

Orbital biotech manufacturing platforms · US

9.0
3

BioServe Space Technologies

ISS life science payload hardware · US

8.8
4

Space Cargo Unlimited

Autonomous orbital biotech infrastructure · LU

8.7
5

LambdaVision

Microgravity protein retina manufacturing · US

8.6
6

Yuri

Orbital biotech laboratories and mission services · DE

8.6
7

Redwire

Microgravity biotech, bioprinting and pharma payloads · US

8.3
8

Space Tango

Automated microgravity biotech research and manufacturing · US

8.2
9

Interstellar Lab

Autonomous plant biotechnology for Earth and space · US

8.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 9 companies in the space biotech industry. In Space Biotech Industry Statistics. Gitnux. https://gitnux.org/space-biotech-industry-statistics/#top-companies

04 Statistics

Technology

Technology evidence centers on orbital biomanufacturing hardware and reduced-gravity production systems, including a $10 million SEARF orbital fabrication laboratory and a February 25, 2025 biomanufacturing patent.

R&D, patents and design rights in the space biotech industry

  • Up to $10 million was awarded for an orbital fabrication laboratory intended to enable microgravity biomanufacturing and Earth reentry of products, under the Texas Space Commission’s SEARF program.[1]
  • Patent 12,234,438 was issued on February 25, 2025 for a biomanufacturing system, method and 3D-bioprinting hardware optimized for reduced-gravity environments.[2]
  • One firm had achieved commercial-scale production of a high-value product in space by 2024, while commercial-scale manufacturing under FDA Good Manufacturing Practice had not yet been achieved or attempted; NASA described InSPA work as underway.[3]

05 Statistics

Market Intelligence

Market sizing depends on definitions, with 2025 estimates spanning $160 million for orbital drug research and $4.75 billion for space-developed or space-manufactured biologics.

Market size, volume and shipments in the space biotech industry

  • $1.50 billion was the global 2025 market size for space-based biopharmaceutical work, defined as spending on microgravity drug discovery, formulation and production services; Dataintelo excludes later ground-manufactured drug sales.[4]
  • $160 million was the global 2025 market size for space-based biopharmaceuticals, covering orbital drug research, development and small-scale production.[5]
  • $4.75 billion was the global 2025 market size for space-based biopharmaceuticals, defined as drugs and biologics developed or manufactured in space, particularly microgravity.[6]

Forecast growth and shipments in the space biotech industry

  • The global space-based biopharmaceuticals market is forecast to reach $1.38 billion in 2035 from $160 million in 2025, implying a 24.0% CAGR; the category covers orbital drug research, development and small-scale production.[5]
  • The global space-based biopharmaceuticals market is forecast to reach $5.07 billion in 2034 from $1.50 billion in 2025, a 14.5% CAGR; the category covers microgravity discovery, formulation and production spending.[4]
  • The global space-based biopharmaceuticals market is forecast to reach $8.12 billion in 2030 from $4.75 billion in 2025, implying an 11.3% CAGR; the category covers space-developed or space-manufactured biologics.[6]

Company counts and size structure in the space biotech industry

  • 40 companies are listed in Space Biotech Hub’s global space-biotechnology company directory, covering firms advancing human health, biomanufacturing, microgravity research and related products.[7]
  • 33 operating companies are tracked globally in in-space manufacturing, a broader category that includes pharmaceutical processing, bioprinting and other biotechnology alongside non-biological manufacturing.[8]
  • One firm achieved commercial-scale production of a high-value product on the International Space Station in 2024; NASA states that no project had yet achieved commercial-scale biological production overall.[3]

Regional split of the space biotech industry

  • North America accounted for 48.0% of global space-based biopharmaceutical spending in 2025, according to Dataintelo’s market model.[4]
  • North America was the largest regional market for space-based biopharmaceuticals in 2025, while Asia-Pacific was identified as the fastest-growing region through 2030.[6]
  • North America accounted for $80.0 million of the global space-based biopharmaceutical market in 2025, versus $35.2 million for Asia-Pacific and $32.0 million for Europe.[5]

Key questions about the space biotech industry

How large is the space biotech market in 2025?
The global 2025 market size for space-based biopharmaceutical work was $1.50 billion. Another defined slice lists $160 million for space-based biopharmaceuticals covering orbital drug research, development and small-scale production.
What growth rates are forecast for space-based biopharmaceuticals?
The $160 million 2025 baseline is forecast to reach $1.38 billion in 2035, implying a 24.0% CAGR. A separate forecast places $1.50 billion in 2025 to $5.07 billion in 2034 at a 14.5% CAGR, and $4.75 billion in 2025 to $8.12 billion in 2030 at an 11.3% CAGR.
Which companies lead the space biotech industry?
Varda Space Industries stands out for orbital pharmaceutical materials processing because it returns pharmaceutical materials to Earth using its W-Series vehicles, while Sierra Space focuses on orbital biotech and pharmaceutical manufacturing since it develops platforms on commercial space stations.
What technology shift is most visible across recent activity?
Automation is a recurring driver of higher orbital throughput, including Exobiosphere’s automated Orbital High-Throughput Screening platform intended to run thousands of experiments with matched ground controls.
How is the industry structured among stakeholders?
The ecosystem stays fragmented across research agencies, launch and station operators, pharmaceutical partners, and specialist startups rather than a single published market-share leader. ISS National Lab listed 331 financial and corporate investor participants in FY2025.
What regulatory constraints affect Earth-intended biotech products?
NASA’s FY2026–27 STTR program requires biotechnology products developed for Earth applications to meet FDA standards. Clinical development remains subject to FDA requirements, as illustrated by Aspera Biomedicines’ drug entering trials under an active Investigational New Drug status.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Space Biotech Industry Statistics. Gitnux. https://gitnux.org/space-biotech-industry-statistics
MLA
Samuel Norberg. "Space Biotech Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/space-biotech-industry-statistics.
Chicago
Samuel Norberg. 2026. "Space Biotech Industry Statistics." Gitnux. https://gitnux.org/space-biotech-industry-statistics.